1	Brain activity measured by functional brain imaging predicts breathlessness improvement
2	during pulmonary rehabilitation
3	
4	Sarah L. Finnegan <sup>1</sup> ( <u>sarah.finnegan@ndcn.ox.ac.uk</u> )
5	Michael Browning <sup>5,6</sup>
6	Eugene Duff <sup>7</sup>
7	Catherine J. Harmer <sup>5,6</sup>
8	Andrea Reinecke <sup>5</sup>
9	Najib M. Rahman <sup>3,4</sup>
10	Kyle T.S. Pattinson <sup>1</sup> (kyle.pattinson@nda.ox.ac.uk)
11	
12	
13	<sup>1</sup> Wellcome Centre for Integrative Neuroimaging and Nuffield Division of Anaesthetics, Nuffield
14	Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
15	<sup>2</sup> Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
16	<sup>3</sup> Nuffield Department of Medicine, University of Oxford, Oxford, UK
17	<sup>4</sup> Oxford NIHR Biomedical Research Centre, Oxford OX3 7JX
18	<sup>5</sup> . Department of Psychiatry, Medical Sciences, University of Oxford, Oxford, UK;
19	<sup>6</sup> . Oxford Health NHS Foundation Trust, Warneford Hospital Oxford
20	<sup>7</sup> . Department of Paediatrics, Medical Sciences Division, University of Oxford, Oxford, UK
21	
22	Corresponding author: Sarah L. Finnegan; sarah.finnegan@ndcn.ox.ac.uk
23	6 <sup>th</sup> Floor, West Wing, John Radcliffe Hospital, Oxford, OX3 9DU; 01865 234 544
24	
25	
26	
27	Research in context
28	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 Evidence before the study. Despite considerable research we still do not know which patient 30 characteristics predict clinical improvements in breathlessness following pulmonary 31 rehabilitation. Recent evidence suggests that the brain processes associated with 32 breathlessness-expectation play an important contributory role in breathlessness severity. 33 However, this has never been examined as a predictor of pulmonary rehabilitation outcome. The ability to predict outcomes has a number of potential benefits, including identifying targets 34 35 for personalised medicine and the better allocation of scare healthcare resources via parallel 36 care pathways.

37 Added value of the study. This study analysed data from a longitudinal experimental 38 medicine study of 71 patients with COPD over a course of pulmonary rehabilitation, that used 39 functional magnetic resonance imaging testing breathlessness-expectation mechanisms in 40 the brain. Participants were randomised in a double-blind procedure to receive either 250mg 41 oral D-cycloserine or a matched placebo. Using baseline variables to train machine learning 42 models we revealed that only models containing brain markers of breathlessness-expectation 43 successfully predicted improvements in dyspnoea-12 score (sensitivity 0.88, specificity 0.77). 44 D-cycloserine use was independently associated with breathlessness improvements. Models 45 that only contained questionnaire and clinical measure did not predict outcome (sensitivity 46 0.68, specificity 0.2).

Implications of all the available evidence. These findings are the first evidence that breathlessness-expectation related brain activity is a strong predictor of clinical improvement in breathlessness over pulmonary rehabilitation. This implies that expectation is a key mechanism in breathlessness perception and that the manipulation of the brain's expectation pathways merits further testing as a novel therapeutic approach for breathlessness.

52

### 54 Abstract

55 Background: Chronic breathlessness in COPD is effectively treated with pulmonary 56 rehabilitation. However, baseline patient characteristics predicting improvements in breathlessness are unknown. This knowledge may provide better understanding of the 57 58 mechanisms engaged in treating breathlessness, helping to individualise therapy. Increasing 59 evidence supports the role of expectation (i.e. placebo and nocebo effects) in breathlessness 60 perception. In this study, we tested functional brain imaging markers of breathlessness 61 expectation as predictors of therapeutic response to pulmonary rehabilitation, and whether D-62 cycloserine, a brain-active drug known to influence expectation mechanisms, modulates any 63 predictive model.

Methods: Data from 72 participants with mild-to-moderate COPD recruited to a randomised double-blind controlled experimental medicine study of D-cycloserine given during pulmonary rehabilitation was analysed (ID: NCT01985750). Baseline variables, including brain-activity, self-report questionnaires responses, clinical measures of respiratory function and drug allocation were used to train machine-learning models to predict the outcome, a minimally clinically relevant change in the dyspnoea-12 score.

Findings: Only models that included brain imaging markers of breathlessness-expectation
successfully predicted improvements in dyspnoea-12 score (sensitivity 0.88, specificity 0.77).
D-cycloserine was independently associated with breathlessness improvement. Models that
included only questionnaires and clinical measures did not predict outcome (sensitivity 0.68,
specificity 0.2).

Interpretation: Brain activity to breathlessness related cues is a strong predictor of clinical improvement in breathlessness over pulmonary rehabilitation. This implies that expectation is key in breathlessness perception. Manipulation of the brain's expectation pathways (either pharmacological or non-pharmacological) merits further testing in the treatment of chronic breathlessness.

- 80 Funding
- 81 This work was supported by the JABBS Foundation

#### 82 Introduction

83 Chronic breathlessness is a key feature of chronic obstructive pulmonary disease (COPD) 84 with symptoms often persisting despite maximal medical therapy. Pulmonary rehabilitation is 85 the best treatment for chronic breathlessness in COPD [1] but the response is variable. Thirty 86 percent of people who complete pulmonary rehabilitation derive no clinical benefit [2]. Despite 87 considerable research, we still do not know which patient characteristics predict beneficial 88 response to pulmonary rehabilitation [2-5]. The ability to predict outcome has a number of 89 potential benefits. These include improving our understanding of underlying mechanisms, 90 identifying targets for personalised medicine, and may allow more accurate allocation of 91 scarce healthcare resources.

92

93 Breathlessness severity is often poorly explained by objective clinical measures [6]. This has 94 prompted research into identifying brain perceptual mechanisms that may explain this 95 discordance. A body of work has recently identified that brain processes relating to expectation 96 (akin to placebo and nocebo effects) have an important role in contributing to breathlessness 97 severity. Whether brain-derived metrics may help predict outcome from pulmonary 98 rehabilitation is unknown, and prediction models until now have not included measures of 99 expectation.

100

101 Between-subject variability in therapeutic response is increasingly recognised as a confounder 102 in clinical trials. A personalised medicine approach aims to identify subgroups of patients that 103 respond to a specific therapy. In psychiatry, brain-derived metrics using functional 104 neuroimaging have taken similar approaches to identifying subtypes of depression that may 105 respond to bespoke therapies [7]. Such techniques rely on biomarkers, which may consist of 106 predictive combinations of biochemical, genetic, demographic, physiological or cognitive 107 measures. In the context of treating breathlessness, predictive biomarkers could pave the way 108 for novel pharmacological and non-pharmacological treatments. These may either work as 109 standalone therapies, or by enhancing other therapies, such as pulmonary rehabilitation.

110

111 In this study, we aimed to predict improvements in breathlessness during pulmonary 112 rehabilitation by analysing baseline data from a longitudinal experimental medicine study of 113 D-cycloserine upon breathlessness during pulmonary rehabilitation. We selected D-114 cycloserine, which is a partial agonist at the NMDA receptor in the brain, for its action on neural 115 plasticity and influence on brain expectation mechanisms associated with cognitive 116 behavioural therapies [8-10]. Brain based pharmacological adjuncts may be one opportunity to boost the effects of pulmonary rehabilitation. We hypothesised baseline brain activity in 117 118 response to breathlessness-related expectation would predict improvement in breathlessness 119 over pulmonary rehabilitation, and that if D-cycloserine indeed had an effect upon expectation 120 then it would emerge as a significant factor in the prediction model. Given that moderators of 121 treatment success of pharmacological agents such as D-cvcloserine remain unclear, this 122 information will not only help us build a better picture of the brain-behaviour changes that may 123 underly response to pulmonary rehabilitation and therefore its potential value as a therapeutic 124 target.

## 126 Methods and Materials

127 A brief overview of materials and methods is presented here with full details included within the supplementary materials. The study and statistical analysis plan were pre-registered on 128 129 bioXIV (https://osf.io/bfqds/). This was an analysis of data from a longitudinal experimental 130 medicine study of patients with COPD over a course of pulmonary rehabilitation. Parts of the 131 study were first published in a characterisation of baseline patient clusters [11] and subsequently in the investigation of the effect of D-cycloserine on brain activity (preprint -132 133 https://tinyurl.com/3pyupwkj). The analysis conducted for this study is novel, not previously reported and is the first use of predictive analysis using this dataset. 134

135

# 136 Participants

137 71 participants (18 female, median age 71 years (46-85 years)) (Supplementary Table 1) were 138 recruited immediately prior to enrolment in a National Health Service-prescribed course of 139 pulmonary rehabilitation. Written informed consent was obtained from all participants prior to 140 the start of the study. Study approval was granted by South Central Oxford REC B (Ref: 141 118784, Ethics number: 12/SC/0713). Full demographic details are included within the 142 supplementary materials and are published separately (preprint is available at 143 https://tinyurl.com/3pyupwkj).

144

# 145 Study Protocol

Data for this analysis were acquired at baseline assessment held at the start of a pulmonary rehabilitation course, and following completion of the pulmonary rehabilitation at 6-8 weeks. At each study visit, identical measures were collected. Following the first visit, participants were randomized in a double-blind procedure to receive either 250mg oral D-cycloserine or a matched placebo. Participants received a single dose on four occasions 30 minutes prior to the onset of the first four pulmonary rehabilitation sessions.

152

Self-report questionnaires: All questionnaires were scored according to respective manuals: Dyspnoea-12 (D12) Questionnaire [12], Centre for Epidemiologic Studies Depression Scale (CES-D) [13], Trait Anxiety Inventory (TRAIT) [14], Fatigue Severity Scale [15], St George's Respiratory Questionnaire (SGRQ) [16], Medical Research Council (MRC) breathlessness scale [17], Breathlessness catastrophising scale, adapted from the Catastrophic Thinking Scale in Asthma [18], Breathlessness vigilance, adapted from the Pain Awareness and Vigilance Scale Breathlessness Awareness and Vigilance Scale [19].

160

161 *Physiological Measures:* Spirometry and two Modified Shuttle Walk Tests (MSWT) were 162 collected using standard protocols [20, 21]. Participant height and weight were recorded at 163 each visit. Arterial oxygen saturations were collected at rest and following the MSWT.

164

## 165 *MRI Measures*

*Image acquisition:* Magnetic resonance imaging of the brain was carried out using a Siemens 3T MAGNETOM Trio. A T1-weighted (MPRAGE) structural scan (voxel size: 1 x 1 x 1 mm) was collected and used for registration purposes. A T2\*-weighted, gradient echo planar image (EPI) scan sequence (TR, 3000ms; TE 30ms; voxel size: 3 x 3 x 3 mm) was used to collect functional imaging data during the word cue task.

171

172 Word cue task: Given sufficient fearful breathlessness exposures, the suggestion alone of the 173 situation can be sufficient to drive a top-down neural cascade and produce breathlessness in 174 the absence of afferent inputs. We drew on this link to probe the neural responses of 175 breathlessness-related expectation by examining the activity of brain regions responding to 176 breathlessness-related word cues [22, 23]. Brain activity was correlated with corresponding 177 visual analogue ratings of breathlessness and breathlessness-anxiety collected during 178 scanning. During the fMRI scanning, participants were presented with a word cue, e.g., "climbing stairs" in white text on a black background for 7 seconds. Participants were then 179 180 asked, "how breathless would this make you feel" (wB) and "how anxious would this make you

181 feel" (wA). To each question participants responded within a 7 second window using a button 182 box and visual analogue scale (VAS). The response marker always initially appeared at the 183 centre of the scale, with the anchors "Not at all" and "Very much" at either end. Scan duration 184 was 7 minutes and 33 seconds.

185 186

# 187 Analysis

188

# 189 Regions of interest

190 15 regions of interest were selected a-priori (Figure 1), encompassing regions associated with 191 sensory and affective processing of breathlessness as well as body, symptom perception and 192 emotional salience [22, 24, 25]. Regions were defined by standard anatomical atlas maps 193 (Harvard-Oxford Atlas and Destrieux' cortical atlas), thresholded at 40% probability and 194 binarized.



196 *Figure 1.* Region of interest map showing 15 brain areas.

197

195

198 Brain Imaging Analysis

Image processing was carried out using the Oxford Centre for Functional Magnetic Resonance Imaging of Brain Software Library (FMRIB, Oxford, UK; FSL version 5.0.8; https://ww.fmrib.ox.ac.uk/fsl/), MATLAB R2018b (Mathworks, Natick, MA) and associated custom scripts. Functional MRI processing was performed using FEAT (FMRI Expert Analysis Tool, within the FSL package).

204

# 205 **Pre-processing and single subject models**

206 Data were pre-processed according to standard protocols which included motion correction 207 and physiological noise removal, before being entered into single subject general linear 208 models. These models captured brain activity during the periods in which the breathlessness-209 related word cues were presented allowing us to examine expectation-related processes 210 (Supplementary Figure 3). Further details regarding pre-processing and model specifics can 211 be found within the supplementary materials. For each participant the mean signal in response 212 to the breathlessness-related word cues was extracted for each brain region (Figure 1). This 213 gave each participant 15 brain-derived scores to enter into the predictive models.

214

# 215 Definition of response to pulmonary rehabilitation

216 Responsiveness to pulmonary rehabilitation was defined as a change in D12 score, a well-217 validated clinical measure of breathlessness, of three or more points, consistent with the 218 minimal clinically important difference (MCID) [12]. To examine whether baseline D12 score 219 differed significantly between responders and non-responders to pulmonary rehabilitation we 220 conducted a comparison of mean baseline D12 score. In addition, a single logistic regression 221 model was applied to the data using MATLAB's mnrfit function to examine whether baseline 222 D12 explained pulmonary rehabilitation outcome over and above the best model prediction. Significance was set as False Discovery Rate (FDR) corrected p<0.05. 223

224

# 225 Predictive Models

226 Table 1. List of measures included within each of the three models (indicated by "x"). Drug ID labels 227 corresponded to whether the participant received D-cycloserine or placebo. Dyspnoea-12 (D12), Centre 228 for Epidemiologic Studies Depression Scale (CES-D), Trait Anxiety Inventory (TRAIT), Fatigue Severity 229 Scale (FSS), St George's Respiratory Questionnaire (SGRQ), Medical Research Council (MRC) 230 breathlessness scale, Breathlessness catastrophising scale (BCS), Heart Rate (HR), Oxygen 231 Saturation (Sats).

Brain & non imaging Included data Brain only Non imaging measures model measure model model Drug ID Х Х х Responder or non-responder х х х label **Brain activity** Amygdala х х Hippocampus х х Anterior insula х х Anterior cingulate х х Posterior insula х х Putamen х х Superior marginal gyrus х х Superior frontal gyrus х х Precuneus х х Medial prefrontal cortex х х Caudate х х Posterior cingulate х х Angular gyrus Х х Precentral gyrus х х Middle frontal gyrus х х Questionnaires D12 х х CES-D х х TRAIT х х FSS х х SGRQ х х MRC х х BCS Х Х Vigilance х Х Physiology FEV1/FVC х х

MSWT – HR change	x	х
MSWT – Sats change	x	х
MSWT – Distance	x	х
MSWT – BORG change	x	х
BMI	x	х
Pack Years	x	х
Age	х	х
Sex	Х	Х

232

233

Physiological Measures: Spirometry and two Modified Shuttle Walk Tests (MSWT) were 234 collected using standard protocols [20, 21]. Participant height and weight were recorded at 235 236 each visit. Sex was self-reported. Arterial oxygen saturations were collected at rest and 237 following the MSWT.

238

239 Models were programmed using R version 3.6.1 (2019-07-05). Modelling procedure remained 240 the same for each of the three models (Figure 2).

- 241 1. All measures were centred and scaled. Checks were performed to determine whether 242 any measures were highly correlated (R>0.8) or linear combinations of each other (Supplementary Figure 3). 243
- 244 2. To correct for imbalance in the number of responders/non-responder a resampling procedure. Imbalanced classes can affect classifier performance. Random 245 246 OverSample Examples (ROSE) was carried out. ROSE, an R package, creates an 247 artificially balanced sample using a smoothed bootstrap approach [26].
- 3. An elastic net procedure was used to identify the number most relevant features for 248 inclusion into the model. Elastic net procedure was selected for its ability to regularise, 249 improve data sparsity via feature selection and cluster correlated measures together 250 251 (for more details see supplementary materials). Features were selected based on ranked coefficients. 252

4. Model training parameters – C, kappa and sigma were selected based on an internal repeated cross-validation procedure (10-fold cross validation repeated 3 times). In all instances automated tuning parameter selection for the values, with a tune length of 5, was utilised within R's *caret* package. Train-test data were kept separate across folds, with the algorithm never having access to the entire dataset. The best tuning parameters were selected automatically by R's *caret* package from across cross validation folds.

- 260 5. These parameters were used to train a Support Vector Classifier (SVC) with radial
  261 kernel to predict outcomes in the entire dataset.
- Model performance was assessed internally using accuracy, sensitivity, specificity and
   area under the curve (AUC). Full confusion matrices are presented. Model significance
   was assessed with a one-tailed binomial test of model accuracy compared to the null
   information rate.



267 Figure 2. A schematic of the modelling procedure adapted from an illustration by Chekroud and 268 colleagues [27]. 1. Participants received two labels, the first corresponding to drug or placebo and the 269 second "responder" or "non-responder" to treatment. 2. An elastic net procedure was used to rank and 270 select the top features. 3. Selected features were used to develop model training parameters in a 271 repeated-cross validation procedure in which the algorithm never has access to the entire dataset. 4. 272 The Trained SVM was then provided with the entire dataset to classify. In addition to model statistics,

- 273 full confusion matrices were output to assess sensitivity and specificity.
- 274
- 275

# 276

### Results 277

### 278 **Responders and non-responders**

279 41 / 71 participants in the primary dataset met the criteria of a change in D12 score of three or more points to be considered a responder [12] (24 D-cycloserine, 17 placebo), and 30 did 280 not (13 D-cycloserine, 17 placebo). No significant interaction between responders and non-281 282 responders and drug was identified using Chi squared analysis ((1,N=71) = 1.6, p=0.21).

283

#### 284 Feature selection – brain imaging only model

285 The elastic net procedure identified 13 of 15 brain derived metrics and drug as relevant for 286 model inclusion. These features were: brain activity within amygdala, caudate, prefrontal 287 cortex, hippocampus, superior frontal gyrus, anterior insula, drug, posterior cingulate cortex, putamen, posterior insula, middle frontal gyrus, precuneus, precentral gyrus and angular 288 289 gyrus.

290

### 291 Feature selection – brain and non-imaging measure model

292 The elastic net procedure identified 12 of 15 brain derived metrics, 13 of 20 non-imaging 293 measures including drug as relevant for model inclusion. These features were brain activity 294 within: superior frontal gyrus, hippocampus, angular gyrus, superior marginal gyrus, 295 amygdala, prefrontal cortex, precuneus, anterior cingulate cortex, anterior insula, middle 296 frontal gyrus, posterior insula and putamen. Behavioural features identified as relevant for 297 model inclusion were D12, anxiety, depression, MRC, the three St George's domains (active, 298 impact, symptoms), MWST BORG, heart rate and Sats change, fatigue, age and BMI.

299

### Feature selection – non-imaging measures model 300

301 Of the 20 questionnaire and physiological features available, only D12 survived the feature 302 selection process.

#### 304 Model results - Internal validation

- 305 Three models with variables selected by the elastic net procedure were assessed for their
- 306 ability to discriminate responders from non-responders (Table 3).
- 307
- 308 The combination of brain and behaviour metrics produced the best classification performance
- 309 (accuracy - 0.83 (95% CI 0.75-0.90); sensitivity - 0.88; specificity - 0.77; p<0.001) (Table 3).
- 310 Weighted variable importance was found to be similar across features, as demonstrated by
- 311 the thickness of the lines in Figure 3. The brain only model was able to correctly categorise
- 312 participants with statistically significant likelihood (accuracy 0.70 (95% CI 0.58-0.81).
- 313

- 315 Table 2. Logistic regression coefficients for predictive power of the computationally derived brain-
- behaviour model (model prediction labels), and baseline D12 on pulmonary rehabilitation outcome,
- 317 measured as a change in D12 score above the minimal clinical important difference. Significance is

318 expressed as False Discovery Rate (FDR) -corrected p-values.

	Coefficient	P value
Intercept	3.571	0.007
Model prediction labels	-2.809	<0.001
Baseline D12	0.071	0.191

319

- 320
- 321

322 Table 3. Model statistics for brain imaging only, brain and non-imaging measure models and non-

323 imaging measures only model. All models contained Drug ID as an additional term. AUC – area under

324 the curve. CI – confidence interval. P-value is expressed as the result of a one-tailed binomial test of

325 model accuracy compared to the null information rate.

Brain only f model		ly full el	Brain & non-imaging measures full model		Non-imaging measures full model		
Accurac	;y	0.70	)	0.83		0.6	6
95% CI	ļ	58-8	1	0.72-0.	90	0.54-	0.77
Sensitivi	ty	0.93	5	0.88		0.6	68
Specifici	ty	0.40	)	0.77		0.2	20
AUC	AUC		)	0.87		0.7	0
p-value	p-value		*	<0.001	**	0.0	9
Confusi	Confusion		Reference Reference		ence	Reference	
matrice	es	Yes	No	Yes	No	Yes	No
Prediction	Yes	38	18	36	7	28	11
	No	3	12	5	23	13	19

326



329

330 Figure 3. Schematic representation of the best predictive model. Predictive brain imaging and non-331 imaging measures are shown linked to treatment response by weighted lines, indicating variable

332 importance. MSWT – Modified Shuttle Walk Test; Sats – Oxygen saturation; HR – Heart Rate; MRC –

- 333 Medical Research Council;
- 334

### 335 Discussion

### 336 Key Findings

337 Using supervised machine learning, this study successfully identified markers that predict 338 clinically relevant improvements in breathlessness over a course of pulmonary rehabilitation. 339 The best model combined brain-imaging markers of breathlessness-expectation, self-report 340 questionnaires and physiology measures, and demonstrated high sensitivity and specificity. 341 Whether or not a participant received D-cycloserine was a significant feature in this model. 342 Our findings demonstrate the first predictive model of change in breathlessness across 343 pulmonary rehabilitation and, for the first time, the clinical relevance of expectation-related 344 brain activity as a therapeutic target in the treatment of breathlessness.

345

346

To date, no study has produced a model capable of predicting an individual's change in breathlessness over pulmonary rehabilitation from baseline traits [2-4]. Although previous studies have shown correlations between baseline variables and outcomes [5], none have attempted to predict outcomes at an individual level. This study is therefore the first to directly predict an individual's change in breathlessness over pulmonary rehabilitation. This was achieved using sensitive brain imaging techniques in order to capture personalised responses to breathlessness expectation which has, until recently remained relatively unexplored.

354

Expectation has been linked with symptom severity across conditions including 355 356 breathlessness and pain [28, 29], and is well recognised to underly the placebo and nocebo 357 effects. An example of the nocebo effect in breathlessness is provided by a study of healthy 358 volunteers in which, using a conditioning paradigm, a harmless odour was initially paired with 359 induced breathlessness. Subsequently, the odour alone was shown to drive brain activity in the periaqueductal gray and anterior cingulate cortex leading to breathlessness despite the 360 absence of afferent respiratory input [29]. In Abdallah et al [30], expectation-related brain 361 362 activity was associated with poorer responses to opioids in breathlessness, potentially

explaining why clinical trials of opioids in the management of breathlessness have beenunsuccessful [31, 32].

365

Fear and anxiety are key components of expectation, which recent research suggests may 366 367 play a key role in the mechanisms and maintenance of breathlessness [22, 33, 34]. Despite 368 this, expectation-related effects have not previously been considered in prediction studies of 369 pulmonary rehabilitation outcome. Our previous work showed a clear correlation between 370 expectation-related brain activity in areas that include the anterior insula, anterior cingulate cortex and prefrontal cortex, and improvements in breathlessness over pulmonary 371 372 rehabilitation [22]. However, while these studies suggest baseline cognitive state may be a 373 therapeutically relevant target, importantly, the methods employed so far did not attempt to 374 predict the response of an individual. Taken together, converging lines of evidence point 375 towards expectation-related processes as a clear potential therapeutic target.

376

In this study we focused on brain activity changes within a set of pre-selected regions of interest associated with breathlessness-expectation and body and symptom perception [22, 24, 25]. In the original trial we hypothesised that D-cycloserine would augment the therapeutic effects of pulmonary rehabilitation across this network, via its effects on neural plasticity and promotion of expectation related learning [10, 35].

382

Using data driven techniques, 13 of the 15 brain derived metrics (and drug) were identified as relevant for model inclusion. Selected brain areas spanned the components of relevant body and symptom perception and emotional salience networks. The resulting brain-only model, while statistically significant (p=0.02) and possessing good sensitivity (0.93), did not distinguish responders from non-responders with sufficient specificity (0.40).

388

By, enriching the brain-only models with questionnaire and physiology measures improved performance considerably. In this enriched model, 12 brain derived metrics and 13 non-

imaging derived metrics, which included self-report questionnaire measures, physiology and
drug, were identified as relevant for model inclusion. Measures of accuracy (0.83), sensitivity
(0.88) and specificity (0.77) all suggest this model was able to significantly (p<0.001) predict</li>
pulmonary rehabilitation outcome.

395

Within the non-imaging measure only model, D12 alone was selected by the elastic net and was not found to be significantly (p=0.09, sensitivity=0.68, specificity=0.20) predictive of pulmonary rehabilitation outcome. No other of the 13 non-imaging derived metrics available was found to contribute to the model. That only D12 was selected suggests that the remaining measures, which were important predictors of rehabilitation outcome in the enriched model, interact strongly with brain activity. These results highlight the value of approaching breathlessness from a multimodal data perspective.

403

404 The retained brain activity features implicate a range of brain networks encompassing 405 functions of cognitive control, symptom perception and sensory integration. Activity within 406 these regions has been shown to predict outcome to cognitive behavioural therapy in social 407 anxiety disorder [36] and obsessive-compulsive disorder [37]. In our paradigm, in which 408 patients were shown breathlessness related word-cues, triggering expectation related 409 processes, activity within cognitive control network may indicate the allocation of attentional resources. The retained questionnaires within the brain and non-imaging measure model 410 411 together highlight another important domain of breathlessness: symptom perception. We suggest that baseline symptom perception may act to directly influence the interpretation of 412 413 the new experiences of pulmonary rehabilitation as positive or negative.

414

D-cycloserine has shown promise in trials examining anxiety, posttraumatic stress disorder and other mental health conditions [8-10], where acute dosages administered prior to exposure based therapies appear to augment changes to expectation, boosting therapeutic effects as a result. As a drug which acts on expectation-related brain activity pathways it is

therefore not surprising that whether a participant received D-cycloserine or placebo was a
retained as a feature in both the brain only model, and to a lesser extent the brain and nonimaging model.

422

## 423 Limitations and future work

424 The major limitation of this study is the lack validation of the model in an external dataset. 425 While some studies hold out a proportion of the original data to create an external validation 426 dataset, this technique was not possible here due to restrictions of sample size. To address 427 these limitations, we used a cross validation approach in which the support vector machine 428 was exposed to multiple iterations of the sub-sampled dataset during model training, and 429 therefore never "saw" the entire dataset until the test phase. Models with a large number of 430 measures compared to events (responder or non-responder) risk overfitting and demonstrate 431 poor generalisability to novel datasets. Our dataset contained 35 potential features and 432 therefore was at risk of overfitting. To address this issue, we reduced the number of data-433 dimensions via feature selection, employed cross-validation and used an automated tuning of 434 the regularisation parameter "C". However, while these techniques may ameliorate some of 435 the risk of overfitting, a future study with larger sample size, or independently collected 436 datasets, would take the next steps to externally validate the brain-behaviour model and allow 437 assessment of generalisability. Finally, a key feature of support vector machines is that they fit high-dimensional discriminatory planes between multiple measures to predict an outcome. 438 439 While this multivariate approach does afford greater sensitivity in distinguishing between nonseparable distributions, it also leads to less intuitive interpretations. Assigning directions to the 440 441 relationships between variables or onto outcomes is not possible with this technique. Thus, 442 the researcher must plan to scrutinise models via interventional studies.

443

444

While larger sample sizes are now required to translate these mechanistic models into clinicalrelevance, the data provides evidence that breathlessness expectation related brain activity

447 at baseline strongly influences how patients respond to treatment in a predictable manner.

448 Further work is now needed in order to move towards model validation and eventual clinical

449 application.

450

451

# 452 Conclusions

This study offers the first steps towards brain-based predictive biomarkers for pulmonary rehabilitation outcome. We have shown that by models including objective brain markers of breathlessness-expectation are able to predict, for the first time, which patients will have clinically important improvements in breathlessness over pulmonary rehabilitation. Such models could reduce the burden of complex decisions placed on the clinicians and pave the way for targeted behavioural and pharmacological interventions.

459

460

461

- 462
- 463

464

466
-00

467	1.	Reijnders, T., et al., The impact of disease-specific fears on outcome measures of
468		pulmonary rehabilitation in patients with COPD. Respiratory Medicine, 2019. 146: p.
469		87-95.
470	2.	Garrod, R., et al., Predictors of success and failure in pulmonary rehabilitation.
471		European Respiratory Journal, 2006. <b>27</b> (4): p. 788.
472	3.	Selzler, A.M., et al., Pulmonary rehabilitation in chronic obstructive pulmonary
473		disease: predictors of program completion and success. Copd, 2012. <b>9</b> (5): p. 538-45.
474	4.	Vagaggini, B., et al., Clinical predictors of the efficacy of a pulmonary rehabilitation
475		programme in patients with COPD. Respir Med, 2009. 103(8): p. 1224-30.
476	5.	Boutou, A.K., et al., An evaluation of factors associated with completion and benefit
477		from pulmonary rehabilitation in COPD. BMJ Open Respir Res, 2014. 1(1): p.
478		e000051.
479	6.	Stefan, M.S., et al., How well do patients and providers agree on the severity of
480		<i>dyspnea?</i> J Hosp Med, 2016. <b>11</b> (10): p. 701-707.
481	7.	Chen, C.H., et al., Brain imaging correlates of depressive symptom severity and
482		predictors of symptom improvement after antidepressant treatment. Biol Psychiatry,
483		2007. <b>62</b> (5): p. 407-14.
484	8.	Ressler, K.J., et al., Cognitive enhancers as adjuncts to psychotherapy: use of D-
485		cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry,
486		2004. <b>61</b> (11): p. 1136-44.
487	9.	Hofmann, S.G., et al., D-Cycloserine as an augmentation strategy with cognitive-
488		behavioral therapy for social anxiety disorder. Am J Psychiatry, 2013. 170(7): p. 751-
489		8.
490	10.	Reinecke, A., et al., Neurocognitive processes in d-cycloserine augmented single-
491		session exposure therapy for anxiety: A randomized placebo-controlled trial.
492		Behaviour Research and Therapy, 2020. <b>129</b> : p. 103607.
493	11.	Finnegan, S.L., et al., Breathlessness in COPD: linking symptom clusters with brain
494		activity. Eur Respir J, 2021.
495	12.	Yorke, J., et al., Quantification of dyspnoea using descriptors: development and initial
496		<i>testing of the Dyspnoea-12.</i> 2010. <b>65</b> (1): p. 21-26.
497	13.	Radloff, L.S., The CES-D Scale: A Self-Report Depression Scale for Research in the
498		General Population. 1977. <b>1</b> (3): p. 385-401.
499	14.	Spielberger, C.D., State-Trait Anxiety Inventory, in The Corsini Encyclopedia of
500		Psychology. 2010.
501	15.	Krupp, L.B., et al., The fatigue severity scale: Application to patients with multiple
502		sclerosis and systemic lupus erythematosus. Archives of Neurology, 1989. 46(10): p.
503		1121-1123.
504	16.	Jones, P.W., et al., A self-complete measure of health status for chronic airflow
505		limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis, 1992.
506		<b>145</b> (6): p. 1321-7.
507	17.	Bestall, J.C., et al., Usefulness of the Medical Research Council (MRC) dyspnoea scale
508		as a measure of disability in patients with chronic obstructive pulmonary disease.
509		Thorax, 1999. <b>54</b> (7): p. 581-586.
510	18.	De Peuter, S., et al., Illness-specific catastrophic thinking and overperception in
511		asthma. Health Psychol, 2008. 27(1): p. 93-9.

512	19.	McCracken, L.M., K.E. Vowles, and C. Eccleston, Acceptance-based treatment for
513		persons with complex, long standing chronic pain: a preliminary analysis of
514		<i>treatment outcome in comparison to a waiting phase.</i> Behav Res Ther, 2005. <b>43</b> (10):
515		р. 1335-46.
516	20.	Bradley, J., et al., Validity of a modified shuttle test in adult cystic fibrosis. Thorax,
517		1999. <b>54</b> (5): p. 437-9.
518	21.	Levy, M.L., et al., Diagnostic spirometry in primary care: Proposed standards for
519		aeneral practice compliant with American Thoracic Society and European Respiratory
520		Society recommendations: a General Practice Airways Group (GPIAG)1 document. in
521		association with the Association for Respiratory Technology & Physiology (ARTP)2
522		and Education for Health3 1 www.apiga.org 2 www.artp.org 3
523		www.educationforhealth.org.uk. Prim Care Respir J. 2009. <b>18</b> (3): p. 130-47.
524	22.	Herigstad, M., et al., Treating breathlessness via the brain: changes in brain activity
525		over a course of pulmonary rehabilitation. Eur Respir J. 2017. <b>50</b> (3).
526	23.	Herigstad, M., et al., Development of a dysphoed word cue set for studies of
527	20.	emotional processing in COPD Respiratory physiology & neurophology 2016 223 n
528		37-42
520	24	Esser B.W. et al. Brain Activation during Percention and Anticipation of Dyspneg in
520	۲.	Chronic Obstructive Pulmonary Disease Frontiers in physiology 2017 8: p. 617-617
521	25	Eaull O.K. A. Haven and K.T.S. Pattinson, Breathlessness and the hody:
522	25.	Neuroimaging clues for the inforential lean. Cortex: a journal devoted to the study of
532		the nervous system and behavior 2017 <b>OF</b> : p. 211, 221
555	26	lie leivous system and benavior, 2017. <b>95</b> . p. 211-221.
554	20.	Lograting Discussed 2014 6(1) p. 82.02
535	27	Learning. R Journal, 2014. <b>6</b> (1): p. 82-92.
530	27.	Chekroud, A.M., et al., Cross-trial prediction of treatment outcome in depression: a
537	20	machine learning approach. Lancet Psychiatry, 2016. <b>3</b> (3): p. 243-50.
538	28.	Janssens, T. and T. Ritz, Perceived triggers of dstrima: key to symptom perception and
539		management. Clinical and experimental allergy : journal of the British Society for
540		Allergy and Clinical Immunology, 2013. <b>43</b> (9): p. 1000-1008.
541	29.	Vlemincx, E., C. Sprenger, and C. Buchel, Expectation and dyspnea: The
542		neurobiological basis of respiratory nocebo effects. European Respiratory Journal,
543		2021: p. 2003008.
544	30.	Abdallah, S.J., et al., Opioids for breathlessness: psychological and neural factors
545		<i>influencing response variability.</i> European Respiratory Journal, 2019. <b>54</b> (3): p.
546		1900275.
547	31.	Ferreira, D.H., et al., Controlled-Release Oxycodone vs. Placebo in the Treatment of
548		Chronic Breathlessness-A Multisite Randomized Placebo Controlled Trial. J Pain
549		Symptom Manage, 2020. <b>59</b> (3): p. 581-589.
550	32.	Currow, D., et al., Regular, sustained-release morphine for chronic breathlessness: a
551		multicentre, double-blind, randomised, placebo-controlled trial. Thorax, 2020. <b>75</b> (1):
552		р. 50-56.
553	33.	Janssens, T., et al., Dyspnea Perception in COPD: Association Between Anxiety,
554		Dyspnea-Related Fear, and Dyspnea in a Pulmonary Rehabilitation Program. Chest,
555		2011. <b>140</b> (3): p. 618-625.
556	34.	Marlow, L.L., et al., Breathlessness and the brain: the role of expectation. Current
557		Opinion in Supportive and Palliative Care, 2019. <b>13</b> (3).

558 559 560	35.	Monahan, J.B., et al., <i>D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats.</i> Pharmacol Biochem Bebay, 1989, <b>34</b> (3): p. 649-53			
560 561 562 563	36.	Klumpp, H., et al., <i>Prefrontal control and predictors of cognitive behavioral therapy</i> <i>response in social anxiety disorder.</i> Social cognitive and affective neuroscience, 2016. <b>11</b> (4): p. 630-640.			
564 565 566	37.	Falconer, E., et al., <i>Inhibitory neural activity predicts response to cognitive-behavioral therapy for posttraumatic stress disorder</i> . J Clin Psychiatry, 2013. <b>74</b> (9): p. 895-901.			
567					
568	Autho	or contributions			
569	S.L.F	<ul> <li>Acquisition of data, analysis, interpretation, drafting, editing and approving</li> </ul>			
570	manu	script			
571	M.B –	Approval of statistical methods, editing and approving manuscript			
572	E.D – Approval of statistical methods, editing and approving manuscript				
573	C.J.H	<ul> <li>Data interpretation, editing and approving manuscript</li> </ul>			
574	A.R – Data interpretation, editing and approving manuscript				
575	N.J.R – Study interpretation, editing and approving manuscript				
576	K.T.S.P - Study design, interpretation, editing and approving manuscript				
577					
578					
579	Decla	ration of interests			
580	Dr. H	armer has valueless shares in p1vital and serves on their advisory panel. She has			
581	received consultancy payments from p1vital, Zogenix, J&J, Pfizer, Servier, Eli-Lilly, Astr				
582	Zeneca, Lundbeck. Dr. Pattinson is named as co-inventors on a provisional U.K. pater				
583	application titled "Use of cerebral nitric oxide donors in the assessment of the extent o				
584	brain dysfunction following injury. Dr. Rahman, has received consulting fees from Rocke				
585	Medical U.K. Dr Browning has received travel expenses from Lundbeck for attending				

587 for CHDR. The remaining authors have no biomedical financial interests or potential conflicts

conferences, has shares in P1vtial Products Ltd and has acted as a consultant for Jansen and

588 of interest.

586

	-	-
-	o	<u></u>
<b>ר</b>	~	ч
_	J	-

590

### 591 Funding

- 592 This work was supported by the JABBS Foundation. This research was funded in whole, or in
- 593 part, by the Wellcome Trust 203139/Z/16/Z. For the purpose of Open Access, the author has
- 594 applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising
- 595 from this submission.
- CJH is supported by the National Institute for Health Research Biomedical Research Centre 596
- 597 based at Oxford Health NHS Foundation Trust and The University of Oxford, and by the UK
- Medical Research Council. KTSP and NMR are supported by the National Institute for Health 598
- Research Biomedical Research Centre based at Oxford University Hospitals NHS Foundation 599
- 600 Trust and the University of Oxford. AR is funded by a fellowship from MQ: Transforming Mental
- 601 Health.